Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[18F]fluoro-4-deoxyfructose
- Development stage
- Unknown
- Lead developer
- University of Ottawa Heart Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
4-[18F]fluoro-4-deoxyfructose (NeuCaVis) is a first-in-class, small molecule radiopharmaceutical PET imaging tracer developed by Yellowbird Diagnostics in collaboration with the University of Ottawa and the University of Ottawa Heart Institute. It is a radiolabeled fructose analog designed to visualize active inflammation and cancer by targeting fructose metabolism (fructolysis). Unlike glucose-based tracers like [18F]FDG, which exhibit high background uptake in healthy brain and heart tissues, 4-[18F]fluoro-4-deoxyfructose shows minimal background signal in healthy tissues because they utilize very little fructose. Upon entering cells via the fructose transporter GLUT5 (SLC2A5), it is phosphorylated by ketohexokinase (KHK) to form 4-fluoro-4-deoxyfructose-1-phosphate. The C4-fluorination prevents aldolase-mediated cleavage, trapping the radiolabeled metabolite intracellularly. It is currently in Phase I clinical development for imaging neuroinflammation, cardioinflammation, and certain cancers such as lymphoblastic T-cell lymphoma.
- Brand names
- NeuCaVis
- Other names
- 4-FDF4-fluoro-4-deoxyfructose4-[18F]fluoro-4-deoxy-D-fructose[18F]4-FDF[18F]4-fluoro-4-deoxy-D-fructose[18F]4-fluoro-4-deoxyfructose
02
Targets
KHK (Ketohexokinase)GLUT5 (Glucose transporter 5)
Beyond the preview
Go deeper on 4-[18F]fluoro-4-deoxyfructose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-[18F]fluoro-4-deoxyfructose.